March 6 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Valeant completes approximately $1.1 billion pay down of senior secured term loans from divestitures; to seek refinancing and amendment of credit agreement
* Valeant - refinancing is expected to have effect of extending maturity date of revolving facility and term b loans that mature prior to 2022
* Valeant - refinancing is expected to have effect of repaying all of outstanding term a loans, removing maintenance covenants from term b loans
* Valeant -seeking to refinance, amend co's existing credit agreement borrow new term b loans under credit agreement and issue new secured debt securities
* Valeant - refinancing to have effect of removing maintenance covenants from term b loans, modifying maintenance covenants under revolving facility
* Valeant - refinancing is subject to market and other conditions and is anticipated to close in q1 of 2017 Source text for Eikon: ID:nPn9WfB9wa Further company coverage: VRX.TO